TC |
Stat |
Stk |
Ins |
Fil |
+d |
+w |
+m |
+q |
+h |
+y |
avg |
|---|
Filing Date |
T Date |
Ticker |
Issuer | Inc | Sector |
Ind | Industry |
Owner |
oSt |
Rel |
Title |
T |
TVal |
Price |
L |
Qty |
oc |
Own |
H |
r2y |
r1y |
r6m |
r3m |
r6w |
r3w |
r7d |
r3d |
f1d |
f1w |
f1m |
f3m |
f6m |
f1y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
9/16/22 19:30 | 9/15/22 | CDAK | Codiak Biosciences, Inc. | DE | Health | BioPrd | Biological Products, (No Diag | Flagship Ventures Fund V General Partner LLC | MA | T | P.d | 0 | 0.00 | 0 | 933 | 36 | 3,541 | I | |||||||||||||||
10/29/20 16:58 | 10/27/20 | FHTX | Foghorn Therapeutics Inc. | DE | Health | Drug | Pharmaceutical Preparations | Flagship Ventures Fund V General Partner LLC | MA | T | P.d | 2,400 | 16.00 | 0 | 150 | 9 | 1,852 | I | |||||||||||||||
10/20/20 20:05 | 10/16/20 | CDAK | Codiak Biosciences, Inc. | DE | Health | BioPrd | Biological Products, (No Diag | Flagship Ventures Fund V General Partner LLC | MA | T | P.d | 2,475 | 15.00 | 0 | 165 | 11 | 1,629 | I | |||||||||||||||
3/6/19 16:45 | 3/4/19 | KLDO | Kaleido Biosciences, Inc. | DE | Health | BioPrd | Biological Products, (No Diag | Flagship Ventures Fund V General Partner LLC | MA | DT | P.d | 14,000 | 15.00 | 0 | 933 | 24 | 4,744 | I | |||||||||||||||
5/15/18 20:41 | 5/11/18 | EVLO | Evelo Biosciences, Inc. | DE | Health | Drug | Pharmaceutical Preparations | Flagship Ventures Fund V General Partner LLC | MA | T | P.d | 4,500 | 16.00 | 0 | 281 | 2 | 18,233 | I |
| D | Derivative transaction in filing (usually option exercise) |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| A | Amended filing |
| E | Error detected in filing |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |